home / stock / ruby / ruby news

RUBY News and Press, Rubius Therapeutics Inc. From 01/13/20

Stock Information
Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com
Menu
RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...
RUBY - Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference

RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and Ready to Supply Future Clinical Trials Focus on Clinical Development to Advance Three Distinct Therapeutic...
RUBY - Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer

CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Laurence Turka, M...

RUBY - Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced today that Pablo J. Cagnoni, M.D., ch...

RUBY - New medical chief at Rubius Therapeutics

Rubius Therapeutics (NASDAQ: RUBY ) appoints  Christina Coughlin, M.D., Ph.D., as the Company’s Chief Medical Officer (CMO), effective January 6, 2020. More news on: Rubius Therapeutics, Inc., Healthcare stocks news, Read more ...

RUBY - Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer

CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Christina Coughli...

RUBY - Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

CAMBRIDGE, Mass. , Dec. 19, 2019 /PRNewswire/ --   Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based...

RUBY - Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors

CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Anne Prener, M.D....
RUBY - Homology Medicines gene therapy shows encouraging action in PKU study

Preliminary data from a Phase 1/2 clinical trial, pheNIX , evaluating Homology Medicines' (NASDAQ: FIXX ) gene therapy HMI-102 in patients with phenylketonuria (PKU) showed encouraging action. More news on: Homology Medicines, Inc., Synlogic, Inc., BioMarin Pharmaceutical Inc., Healthc...

RUBY - Rubius Therapeutics (RUBY) Presents At Jefferies Global Healthcare Conference - Slideshow

The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this Read more ...

RUBY - Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity

Aravive's Reverse Merger Path to Public Company Creates Potentially Compelling Overlooked and Underfollowed Investment Opportunity If a company chooses to go public through a reverse merger instead of the more conventional IPO path, it has a higher chance to become an Overlooked and Underf...
Previous 10 Next 10